Bon Natural Life Limited (Nasdaq: BON) has announced an exclusive cooperation agreement with Beijing Huahai Keyuan (Tech) Co., Ltd. for the distribution of its newly launched postbiotic hypoglycemic ingredients. The 36-month contract, valued at $32 million, positions Beijing Huahai Keyuan as BON's exclusive sales partner in China as the company seeks to expand into the global blood sugar health market.
The patented postbiotic ingredient represents a significant advancement in blood glucose management technology. Clinical testing has demonstrated that when taken 10-30 minutes before meals, the formula reduces post-meal glucose spikes by 15-30% within the critical 1-3 hour window after eating. This level of efficacy reportedly rivals or exceeds that of existing market-leading products.
Innovative Approach to Blood Sugar Management
BON's food-derived postbiotic formula offers several advantages over conventional blood sugar control solutions. Beyond its demonstrated efficacy, the product stands out for its safety profile, convenience, and seamless integration into daily routines—factors that typically drive higher user adherence rates.
"As the patent holder of postbiotics with groundbreaking technological advantages, we are fully confident in our ability to succeed in the vast and rapidly expanding postprandial blood glucose control market while establishing a leading position," stated Hu Yongwei, Chairman and CEO of BON.
The timing of this product launch aligns with growing market demand. According to IQVIA's "Global Diabetes Treatment Market Outlook 2025," the postprandial blood glucose control market currently exceeds $30 billion and maintains a compound annual growth rate of 7.5%.
Strategic Market Positioning
BON is pursuing an aggressive intellectual property strategy to protect its innovation, with plans to secure global patent approvals across major markets over the next two years. This approach aims to safeguard the technology while positioning the company for long-term dominance in the metabolic health space.
The company anticipates that its series of hypoglycemic products based on postbiotics will achieve meaningful market advancements over the next 2-3 years. This growth is expected to drive rapid increases in sales and profits while enhancing the company's investment value.
"The growth of this business line will help accelerate the Company's emergence as a key player in blood glucose health—a critical segment within the broader healthcare sector—while positioning it to become a leader in comprehensive blood glucose health solutions," added Yongwei.
Mechanism and Application
The postbiotic hypoglycemic ingredient works by delivering targeted control over post-meal glucose spikes. Unlike many traditional diabetes medications that require prescriptions and may have significant side effects, BON's solution is designed to be food-safe and user-friendly.
This approach addresses a critical need in diabetes management, as postprandial hyperglycemia (elevated blood sugar after meals) is a significant contributor to overall glycemic control and related health complications. By specifically targeting these post-meal spikes, the product offers a complementary approach to existing diabetes management strategies.
With its combination of efficacy, safety, and ease of use, BON believes its postbiotic hypoglycemic ingredient is positioned to disrupt the postprandial blood sugar control sector and capture significant market share in the coming years.
